Huberman Lab
Also in Life Sciences
Science
The Chain: Protein Engineering Podcast
by Cambridge Healthtech Institute
Today: #199 in Science, India on our combined chart.
Chart positions today · Japan
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like The Chain: Protein Engineering Podcast, try…
Radiolab
Also in Science
Flow Radio
Also in Life Sciences
Clinical Pharmacology Podcast with Nathan Teuscher
Also in Life Sciences
Biotech Hangout
Also in Life Sciences
EHA Unplugged
Also in Life Sciences
Ranking history · Japan
No ranking history for this show in Japan over the last 7 days.
Latest episodes
-
Episode: 89 - James E. Crowe, Jr. on AHEAD 100, a New Strategy for Preparing for the Next Pandemic
September 15, 2026 · 47 minYou can’t forecast the next epidemic with precision, so why do we keep building preparedness plans that depend on guessing? Host Dennis Burton, Ph.D., sits down with Jim Crowe, Jr., M.D., professor and director of the Vaccine Center at…
-
Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics
August 11, 2026 · 39 minHow have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with…
-
Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care
July 14, 2026 · 45 minJuly 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we…
-
Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
June 9, 2026 · 54 minAt this year’s PEGS Boston, industry experts gathered on a panel to explore how AI and machine learning are deployed in biologics R&D today. Moderated by Peter M. Tessier, Ph.D., Albert M. Mattocks professor of pharmaceutical sciences and…
-
Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
May 12, 2026 · 47 minMay 12, 2026 | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology that refuses to cooperate. Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab…
Show 7 more episodesShow fewer episodes
-
Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design
April 15, 2026 · 39 minHow is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor of pharmacology at the University of Zurich, joins The Chain to discuss how BindCraft is…
-
Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
March 17, 2026 · 59 minT cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic…
-
Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
February 10, 2026 · 49 minDuring last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics…
-
Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
January 13, 2026 · 44 minHow has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto, discusses his years-long research on cancer immunotherapy, including his time at MD…
-
Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
December 9, 2025 · 27 minDecember 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoughts and insights on BiTE molecules, pegylated molecules, and other biologic molecules and…
-
Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs
November 11, 2025 · 43 minNovember 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The Chain, host Rakesh Dixit speaks with Jallal on the potential…
-
Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability
October 14, 2025 · 34 minAs drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into…
About the show
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.